Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0237 alone or with BCG in NMIBC
NCT06186414Phase 1Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM0237 in non-muscle-invasive bladder cancer (NMIBC) (6 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose limited toxicity at 21 days, Treatment-emergent adverse events up to 5 years and 2 more. Started Jan 2024; status: recruiting.
02
Drugs
SIM0237
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06186414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06186414.